A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo

NCT04492436 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study design was changed

Conditions

Chemotherapy-induced Peripheral Neuropathy

Interventions

DRUG: thrombomodulin alfa
DRUG: Placebo

Sponsor

Veloxis Pharmaceuticals